Mukhopadhyay Debabrata

Featured in: Favicon

Articles

Sequential ATR and PARP inhibition overcomes acquired DNA damaging agent resistance in pancreatic ductal adenocarcinoma - British Journal of Cancer

1 month ago | nature.com | Christian Pilarsky |Mukhopadhyay Debabrata |Christopher Lord

AbstractPancreatic ductal adenocarcinoma (PDAC) remains the most lethal cancer. While DNA damaging agents such as platinum and PARP inhibitors have derived clinical benefits, acquired resistance invariably develops. Hence there is an urgent need for novel therapeutic strategies to overcome acquired resistance. Clinically relevant resistance in PDAC patient-derived cell lines was achieved by extended exposure to chemotherapy agents.

Try JournoFinder For Free

Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.